English
Regional settings| Spread | 0.14 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 76.53 |
| Open | 75.99 |
| 1-Year Change | -11.58% |
| Day's Range | 75.99 - 76.88 |
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products focused on women's health and well-being through early detection and treatment. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The Diagnostics segment offers a range of diagnostics products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a portfolio of solutions for breast cancer care for radiology, pathology and surgery. The GYN Surgical segment offers a range of products, including its NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System as well as its Fluent Fluid Management system. The Skeletal Health segment offers products such as the Horizon DXA, a dual energy x-ray system, which evaluates bone density and performs body composition assessments, and the Fluoroscan Insight FD mini C-arm.
BRIEF: For the three months ended 25 December 2021, Hologic, Inc. revenues decreased 9% to $1.47B. Net income decreased 24% to $499.2M. Revenues reflect Diagnostics segment decrease of 16% to $950.4M, United States segment decrease of 11% to $1.01B, Europe segment decrease of 13% to $295.1M, All Others. segment decrease of 4% to $43.9M. Net income also reflects Diagnostics segment income decrease of 32% to $531.8M.
Common Stock $.01 Par, 03/11, 750M auth., 261,612,000 issd., less 219,000 shs. in Treas. @ $1.5M. Insiders & Strategic holders own 0.49%. . PO 6/90, 805K shares @ $23 by Hambrecht & Quist. 12/07, Co. acquired Cytyc Corporation @ 0.52 shares (60,622,143 shares issd.). 04/08, 2-for-1 stock split.
